Literature DB >> 6433618

Assessment of therapeutic control of anticoagulation.

A Copplestone, S Roath.   

Abstract

The control achieved in two anticoagulant clinics over 1 year was studied. The result of 430 patient years of treatment in 732 patients was assessed. Overall, the patients were maintained in the therapeutic range (British ratio 2.0-4.0) 85% of the time, 'under-anticoagulated' 10% and 'overtreated' 5% of the time. Patients on long-term treatment had better control than those on short-term treatment (87 and 72% of time in therapeutic range, respectively). Short-term patients were 'undertreated' one quarter of the time. Assessment of the percentage of time individual patients spent within the therapeutic range was a useful index: 77% short-term patients and 99% long-term patients were controlled more than half the time; and 30% short-term plus 40% long-term patients were controlled all the time. Two complementary methods of assessing therapeutic control are used. The standard of control compares favourably with other reports, but shows areas where improvements can be made. For assessment of clinical benefit from anticoagulants, close quality control of treatment by such methods is essential.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6433618     DOI: 10.1159/000206622

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  5 in total

Review 1.  Fortnightly review: anticoagulation in heart disease.

Authors:  S M Hardman; M R Cowie
Journal:  BMJ       Date:  1999-01-23

2.  Anticoagulant therapy.

Authors:  R Alonso Roca; N Puche López
Journal:  Br J Gen Pract       Date:  1993-09       Impact factor: 5.386

3.  Computer control of anticoagulant dose for therapeutic management.

Authors:  P J Ryan; M Gilbert; P E Rose
Journal:  BMJ       Date:  1989-11-11

4.  Prospective comparative study of computer programs used for management of warfarin.

Authors:  L Poller; D Wright; M Rowlands
Journal:  J Clin Pathol       Date:  1993-04       Impact factor: 3.411

Review 5.  Time to Revisit the Time in the Therapeutic Range.

Authors:  James A Reiffel
Journal:  J Atr Fibrillation       Date:  2017-02-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.